David Chang, MD, PhD
The FDA has granted a priority review to axicabtagene ciloleucel (KTE-C19; axi-cel) for transplant-ineligible patients with relapsed or refractory non-Hodgkin lymphoma (NHL), according to Kite Pharma, the developer of the CD19-directed chimeric antigen receptor (CAR) T-cell therapy.
The most common grade ≥3 adverse events (AEs) were anemia (43%), neutropenia (39%), decreased neutrophil count (32%), febrile neutropenia (31%), decreased white blood cell count (29%), thrombocytopenia (24%), encephalopathy (21%), and decreased lymphocyte count (20%).
At the primary analysis of 101 patients, the rate of cytokine release syndrome (CRS) dropped to 13% versus 18% at the interim assessment, which included 93 patients. Additionally, neurologic events dropped from 34% in the interim analysis to 28% in the primary assessment. Overall, 43% of patients received tocilizumab and 27% received corticosteroids to resolve CRS.
... to read the full story